Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer
| dc.rights.license | open | en_US |
| dc.contributor.author | ROSELLINI, Pietro | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | AMINTAS, Samuel | |
| dc.contributor.author | CAUMONT, Charline | |
| dc.contributor.author | VEILLON, Remi | |
| dc.contributor.author | GALLAND-GIRODET, Sigolene | |
| dc.contributor.author | CUGUILLIERE, Alain | |
| dc.contributor.author | NGUYEN, Laurent | |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation [ImmunoConcept] | |
| dc.contributor.author | DOMBLIDES, Charlotte | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | GOUVERNEUR, Amandine | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MERLIO, Jean-Philippe | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BEZIN, Julien | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | GIRODET, Pierre-Olivier | |
| dc.date.accessioned | 2023-02-20T13:45:34Z | |
| dc.date.available | 2023-02-20T13:45:34Z | |
| dc.date.issued | 2022-09 | |
| dc.identifier.issn | 1879-0852 (Electronic) 0959-8049 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/172002 | |
| dc.description.abstractEn | BACKGROUND: Mutations in STK11/LKB1 gene present a negative impact on tumour immune microenvironment, especially with concomitant activating KRAS mutation. These recent data may explain a decreased response to immunotherapy treatment in STK11 mutant non-small cell lung cancer (NSCLC). OBJECTIVE: The primary objective is to evaluate, in a real-life setting, overall survival (OS) in patients with NSCLC according to the presence of STK11 mutation. The secondary objective is to assess time to treatment failure (TTF) for the first-line chemotherapy or immunotherapy. METHODS: This observational multicentric study was conducted in Nouvelle-Aquitaine (France), for 24 months. Clinical, histopathological and imagery data were collected in each centre while the next-generation sequencing analysis was performed in Bordeaux Hospital University. Patient's data were longitudinally followed from NSCLC diagnosis date to the occurrence of censoring events (therapeutic failure or death, as applicable) or until the study end date. RESULTS: median OS from the first drug administration was significantly longer for STK11(wt) patients than STK11(mut) patients (16.2 months [11 - nr] versus 4.7 months [2.5-9.4]; Log-rank test P < 0.001). The Presence of STK11 mutation was significantly associated with shortened OS (RR = 2.26 [1.35-3.79], P = 0.002). First-line TTF was significantly shorter in STK11(mut) population and the presence of the mutation was significantly associated with an increase in treatment failures (RR = 1.87 [1.21-2.89], P = 0.005). The type of treatment (chemotherapy, immunotherapy) does not influence the amplitude of reduced TTF in patients with STK11(mut). CONCLUSION: The presence of STK11 mutation is associated with poor prognosis in NSCLC. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | NSCLC | |
| dc.subject.en | STK11 | |
| dc.subject.en | Overall survival | |
| dc.subject.en | TTF | |
| dc.subject.en | Immunotherapy | |
| dc.subject.en | KRAS | |
| dc.title.en | Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer | |
| dc.title.alternative | Eur J Cancer | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.ejca.2022.05.026 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 35759814 | en_US |
| bordeaux.journal | European Journal of Cancer | en_US |
| bordeaux.page | 85-95 | en_US |
| bordeaux.volume | 172 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.institution | CNRS | |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03997235 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-02-20T13:45:47Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Journal%20of%20Cancer&rft.date=2022-09&rft.volume=172&rft.spage=85-95&rft.epage=85-95&rft.eissn=1879-0852%20(Electronic)%200959-8049%20(Linking)&rft.issn=1879-0852%20(Electronic)%200959-8049%20(Linking)&rft.au=ROSELLINI,%20Pietro&AMINTAS,%20Samuel&CAUMONT,%20Charline&VEILLON,%20Remi&GALLAND-GIRODET,%20Sigolene&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||